Skip to main content
Premium Trial:

Request an Annual Quote

Biocept: Michael Dugan

Biocept has appointed Michael Dugan as chief medical officer and medical director, responsible for medical policy decision-making and operations of Biocept's CLIA-certified laboratory. Dugan has more than 25 years of industry experience, most recently as president and CEO of professional advisory group practice MCDXI Medical Diagnostics International. Before that, he was senior medical advisor and chief medical officer of Clinical Genomics. He has also served as senior VP of clinical development and medical affairs at Exact Sciences, medical director at Quest Diagnostics Nichols Institute, chief medical officer at BioTheranostics, VP and chief medical officer at Roche Molecular Systems, and VP of pathology services at Genzyme Genetics.

Dugan received a BS in biology from the University of Notre Dame and a medical degree from the University of Arizona College of Medicine. He completed his post-graduate training in the department of pathology at Yale-New Haven Hospital and in the departments of pathology and laboratory medicine at Childrens Hospital Los Angeles and the University of California, Los Angeles.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.